stockrowSmith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) Operating cash flow
Smith & Nephew SNATS, Inc.'s operating cash flow for fiscal 2025 was $1.3B, up 30.2% from $987.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.1B. Over the past ten years it has ranged from $468.0M (fiscal 2022) to $1.3B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. Smith & Nephew SNATS, Inc. ranks 5th of 149 Medical Devices companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $1.3B | 30.19% |
| FY2024 | $987.0M | 62.34% |
| FY2023 | $608.0M | 29.91% |
| FY2022 | $468.0M | (46.64%) |
| FY2021 | $877.0M | (6.20%) |
| FY2020 | $935.0M | (19.95%) |
| FY2019 | $1.2B | 25.46% |
| FY2018 | $931.0M | (14.59%) |
| FY2017 | $1.1B | 28.39% |
| FY2016 | $849.0M | (17.57%) |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNN Smith & Nephew SNATS, Inc. | $3.1B |
| GMED Globus Medical, Inc. compare | $925.9M |
| PODD Insulet Corporation compare | $509.0M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $468.1M |
| BIO Bio-Rad Laboratories, Inc. compare | $468.1M |
| BRKR Bruker Corporation compare | $341.8M |
| PEN Penumbra, Inc. compare | $261.0M |
| TXG 10x Genomics compare | $127.1M |
| GKOS Glaukos Corporation compare | $47.7M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement